The regulation of megakaryocytopoiesis and thrombopoiesis appears to be under the control of an array of hematopoietic growth factors. To determine the relationship of endogenous thrombopoietic cytokine levels and circulating platelet (PLT) counts, we measured the levels of thrombopoietin (TPO), interleukin-11 in patients with significant thrombocytopenia secondary to both marrow hypoplasia and increased PLT destruction. Increased endogenous levels of TPO and IL-11, but not IL-6, were detected in bone marrow transplant patients with thrombocytopenia following myeloablative therapy (BMT/ MAT) (TPO: 1,455.5 f 87.3 pg/mL, [PLT 39,600 f 7,8OO/pLl, P c .001, n = 12; IL-11: 227.9 f 35 pg/mL, [PLT 32,900 k 5,7OOO/pL], P c .05, n = 19; IL-6 25.8 f 8.4 pg/mL, [PLT 32,800 f 5,O57/pL], P > .05, n = 4) Y normal donors (TPO c150 pg/mL, n = 8; IL-11 <50 pg/mL, n = 9; IL-6 < 10 pa/ mL, n = 5 [PLT 203,000 f 7.5OO/pLl. There was a significant inverse correlation between endogenous Ievels of TPO and IL-11, but not IL-6, and PLT counts in the MAT/BMT patients (TPO: r = -0.57, P < .OOOl, n = 188; IL-11: r = -0.329, P < .OOOl. n = 249; IL-6: r = -0.1147, P> .05, n = 62). In patients HE LIGAND for the c-Mpl proto-oncogene, which is T predominantly produced in the liver and kidney, has recently been purified, cloned from several species, and expressed in mammalian cells.'-6 Recombinant Mpl ligand (thrombopoietin) (PO) has been shown to both enhance megakaryocyte development and to increase the size, number, and ploidy of developing megakary~ctes.~-~~'~* Intraperitoneal injection of mice or neonatal rats with purified ligand results in a 400% increase in the circulating platelet (PLT) c o~n t .~.~, ' TPO, like many other hematopoietic growth factors, exerts its biologic effects through binding of a specific The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact. 0 1996 by The American Society of Hematology. 0006-4971/96/8809-~0009$3.00/0 with immune thrombocytopenia purpura (ITPI, with decreased PLT survival, but intact bone marrow megakaryocytopoiesis, endogenous IL-11 levels were significantly increased (328.0 k 92.6 pg/mL. [PLT 20,900 * 3,OOO/pLl, P < .05, n = 25). However, endogenous TPO levels remained undetectable (~1 5 0 pg/mL, [PLT 30,500 f 5,50O/pL], n = 15). These results suggest that there may be differential mechanisms regulating endogenous TPO, IL-11, and IL-6 levels during acute thrombocytopenia and suggest that the absolute number of circulating PLTs may not always be the sole regulator of endogenous TPO levels. Other mpl-expressing cells of the megakaryocyte lineage may contribute to the regulation of circulating TPO levels as well. Our results also suggest IL-11 levels may in part, be regulated by a negative feedback loop based on circulating PLT counts, but also may, in part, be regulated by a variety of inflammatory agonists. Both TPO and IL-11, therefore, appear t o be active thrombopoietic cytokines regulating, in part, megakaryocytopoiesis during states of acute thrombocytopenia.
The regulation of megakaryocytopoiesis and thrombopoiesis appears to be under the control of an array of hematopoietic growth factors. To determine the relationship of endogenous thrombopoietic cytokine levels and circulating platelet (PLT) counts, we measured the levels of thrombopoietin (TPO), interleukin-11 (IL-111, and interfeukin-6 (IL-6) in patients with significant thrombocytopenia secondary to both marrow hypoplasia and increased PLT destruction. Increased endogenous levels of TPO and IL-11, but not IL-6, were detected in bone marrow transplant patients with thrombocytopenia following myeloablative therapy (BMT/ MAT) (TPO: 1,455.5 f 87.3 pg/mL, [PLT 39,600 f 7,8OO/pLl, P c .001, n = 12; IL-11: 227.9 f 35 pg/mL, [PLT 32,900 k 5,7OOO/pL], P c .05, n = 19; IL-6 25.8 f 8.4 pg/mL, [PLT 32,800 f 5,O57/pL], P > .05, n = 4) Y normal donors (TPO c150 pg/mL, n = 8; IL-11 <50 pg/mL, n = 9; IL-6 < 10 pa/ mL, n = 5 [PLT 203,000 f 7.5OO/pLl. There was a significant inverse correlation between endogenous Ievels of TPO and IL-11, but not IL-6, and PLT counts in the MAT/BMT patients (TPO: r = -0.57, P < .OOOl, n = 188; IL-11: r = -0.329, P < .OOOl. n = 249; IL-6: r = -0.1147, P> .05, n = 62). In patients HE LIGAND for the c-Mpl proto-oncogene, which is T predominantly produced in the liver and kidney, has recently been purified, cloned from several species, and expressed in mammalian cells.'-6 Recombinant Mpl ligand (thrombopoietin) (PO) has been shown to both enhance megakaryocyte development and to increase the size, number, and ploidy of developing megakary~ctes.~-~~'~* Intraperitoneal injection of mice or neonatal rats with purified ligand results in a 400% increase in the circulating platelet (PLT) c o~n t .~.~, ' TPO, like many other hematopoietic growth factors, exerts its biologic effects through binding of a specific < .05, n = 25). However, endogenous TPO levels remained undetectable (~1 5 0 pg/mL, [PLT 30,500 f 5,50O/pL], n = 15). These results suggest that there may be differential mechanisms regulating endogenous TPO, IL-11, and IL-6 levels during acute thrombocytopenia and suggest that the absolute number of circulating PLTs may not always be the sole regulator of endogenous TPO levels. Other mpl-expressing cells of the megakaryocyte lineage may contribute to the regulation of circulating TPO levels as well. Our results also suggest IL-11 levels may in part, be regulated by a negative feedback loop based on circulating PLT counts, but also may, in part, be regulated by a variety of inflammatory agonists. Both TPO and IL-11, therefore, appear t o be active thrombopoietic cytokines regulating, in part, megakaryocytopoiesis during states of acute thrombocytopenia. 0 7996 by The American Society of Hematology.
receptor, the product of the c-Mpl proto-oncogene."" Expression of c-Mpl in mice and humans appears to be restricted to PLTs megakaryocytes, and late progenitors of megakaryocytic lineage.9~'2~'' TPO binding induces tyrosine phosphorylation of a number of substrates, such as Jak2, Shc, and the Mpl receptor itself in human platelet and megakaryocytic cell line^.'^-'^ In addition to its importance in signal transduction, both in vivo and in vitro data suggests that Mpl receptor may be involved in the uptake and metabolism of TPO by PLTS.'~.'' A family of pleiotropic hematopoietic growth factors, with a common signal transduction pathway including interleukin-I I (IL-1 I), IL-6, and leukemia inhibitory factor, has been shown to have various stimulatory effects on megakaryocytopoiesis and PLT production.",*' Within this family, IL-1 1 represents a unique polypeptide, initially cloned from a primate marrow stromal cell line (PU-34)." Preclinical studies in both rodents and nonhuman primates have .demonstrated that IL-I 1 induces significant enhancement of megakaryocytop~iesis.~~-~~ Administration of IL-11 also results in a significant elevation in the PLT count of neonatal rats? bone marrow transplanted mice,z6 and splenectomized mice.24 Recently, a randomized placebo-controlled trial of recombinant human IL-11 (50 Fgkg) lating factor (G-CSF) with neutropenia35 in patients undergoing bone marrow transplant (BMT) after myeloablative therapy (MAT). To determine the relationship of endogenous thrombopoietic cytokine levels with circulating PLT counts and the mechanisms associated with the regulation of these cytokine levels, we measured the circulating levels of TPO, IL-11, and IL-6 in patients with significant thrombocytopenia secondary to both marrow hypoplasia and increased PLT destruction. For personal use only. on August 31, 2017. by guest www.bloodjournal.org From 
MATERIALS AND METHODS

Between
26*
27*
28"
29* for those patients are listed in Table 2 . Plasma samples from newlydiagnosed ITP patients were obtained at diagnosis, 3 to 21 days after diagnosis while PLT counts recovered (2 100,00O/pL), and 6 months after diagnosis. Plasma samples from recurrent ITP patients were obtained during thrombocytopenia episodes, as well as after PLT recovery.
Eight ITP patients were treated at New York Hospital, Comell Medical Center, New York, NY, between May 1991 and September 1994. All other patients were treated at Children's Hospital of Orange County, Orange, CA. Informed consents for blood samples were obtained from the patients or parentdguardians as approved by the Institutional Review Board of both hospitals. Clinical and laboratory data of the patients were obtained from the patient's medical records. Plasma was separated, aliquoted, and stored frozen at -80°C immediately after blood samples were collected, until assay. The TPO levels in plasma were measured by a TPO receptor-antibody mediated sandwich ELISA. A full description of the assay will be published elsewhere.36 Briefly, microtiter plates were coated at 4°C overnight with 100 pL of rabbit F(ab') antihuman Fc (2 mgInL, Jackson Immunoresearch, West Grove, PA) and then incubated for 2 hours at room temperature with 100 pL of a chimeric molecule consisting of human TPO receptor fused to the Fc portion of human lg G (100 ng/mL, Genentech, S. San Francisco, CA). Twofold serial dilution (initial dilution 1:s) of plasma samples and standards were Consent, clinical data, and plasma sample collection.
Enzyme-linked immunosorbent assay (ELISA) for TPO.
added to the wells and incubated for 1 hour. Bound TPO was quantitated colorimetrically by incubation with 100 pL of biotinylated affinity-purified polyclonal rabbit antihuman TPO (Genentech) followed by streptavidin-conjugated peroxidase (Vector, Burlingame, CA) and substrate. Full-length, glycosylated, recombinant human TPO produced by mammalian cells was used to generate standard curves, which were subjected to four parameter nonlinear regression curve fitting. The sensitivity range of the assay was 150 to 1,000 pglmL of TPO. The assay does not cross react with human LL-6 and IL-I 1 . The performance characteristics of the ELISA were similar in plasma and serum and independent of the type of anticoagulant used. The ELISA preferentially detects full-length TP0.37 TPO levels measured by ELISA were further validated by comparable results using the megakaryoblastic HU-3 cell proliferation assay.'x There is a significant positive correlation ( P < ,001) between the stimulatory activity of thrombocytopenic sera determined by HU-3 bioassay and TPO levels determined by the ELISA." Mixing rhTPO at a concentration of 1,000 pg/mL with representative plasma samples and measuring the recovery of rhTPO did not show any interfering substances in the plasma.
Levels of IL-I I were measured by a sandwich ELISA.39 Briefly, microtiter plates were coated with monoclonal anti-rhIL-I1 antibody (Genetics Institute, Cambridge, MA). RhIL-11 standards, blanks, and test samples were added and incubated at room temperature. Biotinylated mouse anti-IL-I1 monoclonal antibody (Genetics Institute) was added and incubated at room temperature. Plates were washed and avidin-conjugated horseradish peroxidase (Vector, Burlingame, CA) was added and incubated for 1 hour at room temperature. Plates were washed and o-phenylenediamine (Sigma, St Louis, MO) was added as the substrate. The reaction was stopped after S minutes by addition of 2.25 m o l n sulfuric acid. Optical density of the samples was measured at 490 nm with a Bio Rad (Richmond, CA) EIA reader. Sensitivity of the assay ranged from 40 to 1,000 pg1mL of IL-1 I . Various concentrations of rhIL-I1 (0 to 5,000 pg1mL) were used for the standard curve. All samples were run in duplicate. IL-1 I levels by ELISA were previously validated by correlating the standard curve with a B 9/11 proliferation assay (performed by Frann Bennett, Genetics Institute).'") Levels of 1L-6 were measured by a sandwich ELISA (Biosource International, Camarillo, CA) according to manufacturer's instructions. Sensitivity of the assay ranged from 2 pg/mL to 500 pg/mL. All samples were run in duplicate.
Results are expressed as mean values 2 standard error of the mean (SEM) of three or more samples. Where appropriate, the probability of significant differences between two groups was determined using the unpaired Student's t-test. The relationship between platelet and cytokine levels was analyzed by linear correlation (Spearman Correlation Test) and regression analysis. Statistical analyses were performed using the InStat statistical program (Graph Pad, San Diego, CA) for the Macintosh computer. P values < .OS were considered significant.
ELISA for detecting human IL-11.
ELISA jor detecting human IL-6.
Statisricaf analysis.
RESULTS
TPO levels in the plasma of MAT/BMTpatients. To determine if plasma levels of TPO protein were altered during thrombocytopenia, 215 plasma samples from 12 patients undergoing MATBMT were assayed for TPO. The mean concentrations of plasma TPO from the 12 patients and the corresponding mean number of PLTs as a function of time following MAT are shown in Fig 1A. Before MAT (day -7) with normal PLT counts (21 1,500 -+ 26,10O/~L), plasma TPO levels were undetectable (< 150 pg/mL). TPO levels MAT days correspond to days -7 to -1. BMT day corresponds to day 0, and the posttransplantation period corresponds to days +1 to +180. A minimum of three plasma samples and a maximum of 11 samples were assayed on any given day. Mean f SEM of the values are presented. *TPO levels at day -7 were all below the minimum detectable level (150 pglmL1 and the actual value of the data is not known. (B) Correlation between plasma TPO levels and PLT counta in pediatric cancer patients undergoing BMT after MAT. The results of 188 samples from 12 patients are plotted. A significant correlation betwean plasma TPO levels and PLT counts was found (r = -0.57, P < .OOOl) using Spearman correlation analy- ? 14,400/pL, P < .001) coinciding with severe thrombocytopenia and a hypoplastic bone marrow. TPO levels remained elevated and by day +40, as the mean PLT counts rose to 80,60O/pL, average TPO levels had decreased to 468.7 t 80 pg/mL. Three months post-BMT, TPO levels (376 2 73.9 pg/mL; PLT: 131 ? 68.4 WpL) were still above the limit of detection, but most returned to baseline levels at 6 months post-BMT, and all patients were below detectability after 9 months (data not shown). As shown in Fig   1   10 100 500
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IB, a significant inverse correlation ( r = -0.57, P < .0001, n = 188) could be demonstrated between TPO plasma levels and PLT counts in MATBMT patients. There were no differences in TPO levels and PLT counts between autologous and allogeneic BMT at various days post-MATBMT (data not shown). The median peak value of TPO was 1451 pg/ mL (range, 989 to 1839 pg/mL). Individual peak values were found at a median of 11.5 days post-BMT (range, day +2 to day +21). Plasma levels of IL-11 were determined in 266 samples from 19 MAT are shown in Fig 2A. Before MAT (day -7) with normal PLT counts, circulating IL-11 levels were below detectability. Circulating IL-11 levels increased during MAT and the early post-BMT period, while PLT counts started to decrease and eventually dropped to their nadir (IL-11 = 239.9 2 36.6 pg/ mL; PLT 32,900 -+ 5,70O/pL, P < .05) at day 5. In contrast to TPO, IL-11 levels increased further after this point and peaked at day 33 post-BMT (467.4 ? 54.9 pg/mL) despite the progress of PLT recovery (PLT: 81,750 2 9,700/pL, P < .001, n = 12). The circulating IL-11 levels gradually decreased in 3 months and returned to near baseline levels by 9 months postBh4T. There was no significant difference in endogenous IL-11 levels between autologous and allogeneic BMT at various days post-MATIBMT (data not shown). A significant correlation of circulating IL-11 levels with PLT counts in MATBMT patients was also demonstrated ( I = -0.329, P < .001, n = 249) (Fig 2B) . Plasma levels of IL-6 were determined in 70 samples from four pediatric cancer patients undergoing MATBMT. The mean plasma levels of IL-6 and the corresponding mean number of PLTs as a function of time following MAT are shown in Fig 3A. Before MAT (day -7) with normal PLT counts, circulating IL-6 levels were less than 5 pg/mL. Circulating IL-6 levels did not significantly change during the course of thrombocytopenia and platelet recovery (Fig 3A) . There was no correlation between the endogenous IL-6 levels and circulating PLT counts (r = -0.1147, P > .371, NS) (Fig 3B) .
A total of nine plasma samples collected from seven patients with thrombocytopenia (median PLT counts 62,OOO/pL; range, 36,00O/pL to 118,00O/pL) secondary to SMAT were assayed for TPO. Significantly elevated TPO levels were observed in all but one sample (median TPO level, 689 pg/mL, range, 361 to 1,227 pg/mL, P < .01).
IL-6 levels in the plasma of MAT/BMT patients.
TPO levels in the plasma of SMAT. 
IL-1 I levels in ITP patients.
The plasma levels of IL-1 I from children with acute ITP at diagnosis were significantly increased when compared to age-matched controls (IL-I 1 :
328.0 -+ 92.6 pg/mL, PLT: 19,000 -t 2,7OO/pL, n = 25, P < .05) (Fig 4) . Fourteen days after diagnosis, PLT counts recovered following treatment. The endogenous IL-1 1 levels, however, remained elevated (IL-11: 530.4 2 159.7 pg/ mL, PLT: 241,000 -+ 38,2OO/pL, n = 13, P < .05), similar to the BMT patients. Six months after diagnosis, the circulating IL-1 I levels had returned to normal levels (66.4 2 20.3 pg/mL, PLT: 282,800 t 46,200/pL, n = 7).
TPO levels in the plasma of ITP patients. A total of 15 plasma samples collected during thrombocytopenia (median PLT counts 30,5OO/pL; range, 6,OOO/pL to 52,0OO/pL) from 15 ITP patients were also assayed for TPO. In contrast to the results with IL-11, all of the ITP patients at diagnosis had undetectable circulating TPO levels (< 150 pg/mL) (Fig  4) . Eleven plasma samples were also obtained from six ITP patients, either after PLT recovery for the newly-diagnosed ITP patients or during clinical remission stage for the recurrent ITP patients (median PLT counts, 154,00O/pL; range, 98,OOO/pL to 355,00O/pL) (Fig 4) . None of these samples had detectable TPO levels either. To rule out the possibility that the plasma of ITP patients contained an inhibitor(s) interfering with the TPO ELISA, plasma samples of ITP patients (Table 2 , patient nos. 11 through 15) were mixed with rhTPO at a concentration of 1,000 pg/mL. The amount of rhTPO measured by ELISA in these samples ranged from 915 pg/mL to 1,173 pg/mL (median, 947 pg/mL), which was not significantly different from that of controls without patient plasma, ruling out the presence of an interfering inhibitor( s).
DISCUSSION
Circulating levels of TPO in patients with thrombocytopenia secondary to various pathological conditions were asFor personal use only. on August 31, 2017 . by guest www.bloodjournal.org From sessed to evaluate the relationship of endogenous TPO levels to the circulating platelet count. Our patient population could be divided into two major groups: MAT/BMT and SMAT patients with thrombocytopenia, decreased PLT production, and bone marrow hypoplasia; and ITP patients with thrombocytopenia, decreased PLT survival, and increased PLT production based on increased bone marrow megakaryoc y t e~.~' Elevated TPO levels from patients with severe thrombocytopenia following myeloablative therapy indicated an inverse relationship between circulating TPO levels and the circulating PLT count. In a recent study, TPO bioactivity in serum from patients undergoing MAT and autolo- gous peripheral blood progenitor cell transplantation was measured by a semiquantitative 32D/huMpl+ bioassay system. Although the patients in that study had a shorter duration of severe thrombocytopenia (about 5 days compared with about 30 days in our patients), an inverse correlation between TPO levels and PLT count, over time, was demonstrated and is consistent with the results presented here?'
Conversely, the TPO levels observed in ITP patients with severe thrombocytopenia remained undetectable (Fig 4) . A mechanism was recently proposed suggesting that in patients with normal liver function, TPO production is constitutive and circulating TPO levels are controlled by the circulating 
--------)
Minimum detectable level of TPO. TPO levels were all below the minimum detectable level and the actual value of the data is not known.
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From PLT mass through Mpl receptor-mediated uptake and metabolism. Consequently, a lower circulating PLT mass would have less capacity for TPO uptake and metabolism, resulting in higher circulating TPO 1e~els.l~ Our results from ITP patients, together with the recent findings that Mpl receptor is expressed not only on PLTs but also on the megakaryocyte and its progenitor^,'^ however, suggest that the absolute number of circulating PLTs may not be the sole regulator of endogenous TPO levels. We propose that circulating TPO levels may be regulated by the total cell mass of the megakaryocyte lineage that expresses Mpl receptor. Therefore, circulating TPO levels may be significantly increased in thrombocytopenic patients with bone marrow hypoplasia due to low amounts of total Mpl receptor-expressing cellular mass. In contrast, despite similar degrees of acute thrombocytopenia, the total number of Mpl receptors, and consequently the TPO catabolism capacity in ITP patients, may be higher due to increased numbers of megakaryocyte progenitor cells, megakaryocytes, and the continuous production of new PLTs, which may still be able to take up TPO before autoimmune clearance, resulting in low or undetectable levels of TPO. Consistent with our hypothesis is the recent observation that low levels of circulating TPO have been demonstrated in transcription factor, NF-E2, knock-out mice, which have a maturation defect with PLT production, but retain high megakaryocyte Ievel~.~' The possible contribution of altered Mpl receptor numbers per cell andor expression patterns of different Mpl receptor variants to the undetectable circulating levels of TPO in ITP patients is currently under investigation.44 Additionally, since increased bone marrow megakaryocytes were observed at diagnosis in all of our ITP patients, it is possible that circulating TPO levels had briefly surged before diagnosis. Because TPO levels could only be measured after diagnosis, this surge may have been missed. Finally, it is possible that small differences in the TPO levels in control patients compared with ITP patients may not have been observed, as our assay did not detect TPO levels below 150 pg/mL. More sensitive ELISAs are being developed to determine if such differences ~c c~r .~~.~~,~~ However, such brief or low level increases would still be considerably different responses than that observed in patients with hypoplastic bone marrows.
Elevated IL-11 levels were observed in both MATBMT patients and in ITP patients (Figs 2 and 4) . A significant inverse correlation between circulating PLT counts and endogenous IL-11 levels was observed in the MAT/BMT patients ( r = -0.329, P < .0001). Bellido et and others have recently demonstrated that IL-1 1 receptors are expressed on megakaryocytic and bone marrow stromal cells.4x We and others have also reported that IL-11 production can be induced by a number of inflammatory agonists, including IL-la, transforming growth factor (TGF) pl and TGFp2. 49, 50 Elevated IL-11 levels in ITP patients indicated that unlike TPO, endogenous IL-11 levels may not be regulated by IL-11 receptor expressing cells. Decreased PLT count in both MAT-treated and ITP patients may be one of the regulators inducing IL-11 production. The prolonged elevation of IL-11, despite PLT recovery, may be due to other inflammatory agonists produced during thrombocytopenia. The relationship between the IL-11 elevation and the expression of these cytokines in vivo, therefore, requires further investigation.
IL-6 is a multifunctional cytokine that increases in vitro megakaryocyte size and megakaryocyte ploidy when combined with IL-3 in ~i t r o .~' .~' Preclinical in vivo studies of IL-6 demonstrated increased PLT production in both mice and primate^.^^,^' Endogenous IL-6 levels in patients with thrombocytopenia secondary to MAT in our study, however, were not correlated with circulating PLT counts (Fig 3) . Our data corroborates previous results that demonstrated the lack of any relationship of circulating PLT counts and IL-6 levels,ss557
In summary, both TPO and IL-11 appear to be important physiological regulators of megakaryocytopoiesis and thrombopoiesis. Endogenous IL-11 levels appear to be regulated by both circulating PLT count and possibly other inflammatory agonists, whereas endogenous TPO levels appear to be regulated by the total Mpl receptor-expressing cellular mass. Further studies are needed to determine the mechanism associated with TPO absorption and metabolism by Mpl receptor expressing cells. Future clinical trials of both TPO and IL-I 1 will help delineate the importance and role of each of the thrombopoietic cytokines in regulating megakaryocytopoiesis, particularly in the context of ITP.
